National Bank of Canada
KROS icon

National Bank of Canada’s Keros Therapeutics KROS Stock Holding History

National Bank of Canada’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$437 – 2917
2024
Q2 		$437 Hold
10
– – ﹤0.01% 2574
2024
Q1 		$543 Sell
10
-20
-67% -$1.19K ﹤0.01% 2593
2023
Q4 		$1.29K Hold
30
– – ﹤0.01% 2513
2023
Q3 		$925 Hold
30
– – ﹤0.01% 2600
2023
Q2 		$1.21K Hold
30
– – ﹤0.01% 2531
2023
Q1 		$1.28K Hold
30
– – ﹤0.01% 2496
2022
Q4 		$1.44K Hold
30
– – ﹤0.01% 2542
2022
Q3 		$1K Hold
30
– – ﹤0.01% 2599
2022
Q2 		$1K Hold
30
– – ﹤0.01% 2694
2022
Q1 		$2K Hold
30
– – ﹤0.01% 2701
2021
Q4 		$2K Buy
+30
New +$1.5K ﹤0.01% 2679

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

National Bank of Canada's KROS Position: Q3 2024 in Review

National Bank of Canada sold out of Keros Therapeutics (KROS) in Q3 2024, closing a stake of 10 shares — an estimated $437 sold.

National Bank of Canada first reported a position in KROS in Q4 2021 and held it in 11 quarters. The position peaked at $2K in Q1 2022. 163 funds tracked by Wall St. Rank hold KROS as of Q3 2024.

  • National Bank of Canada reported no remaining Keros Therapeutics position as of Q3 2024 after selling out during the quarter.
  • National Bank of Canada sold 10 Keros Therapeutics shares in Q3 2024, an estimated $437.
  • National Bank of Canada first reported a position in Keros Therapeutics in Q4 2021 and held it in 11 quarters.
  • National Bank of Canada's Keros Therapeutics position peaked at $2K in Q1 2022.
  • 163 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.